Linaclotide

Gut Health / GI

Also known as: Linzess, Constella

Guanylate Cyclase-C AgonistsResearch phase: FDA-approved, extensive post-marketingRegulatory: FDA-approved (2012, Linzess) for IBS-C and chronic idiopathic constipation.

Mechanism

An FDA-approved oral peptide for IBS with constipation (IBS-C) and chronic constipation. It works on the surface of your intestinal lining to increase fluid secretion and speed up gut motility. It also reduces abdominal pain by decreasing the sensitivity of pain-sensing nerves in the gut.

Technical detail

Fourteen-amino acid synthetic peptide, guanylate cyclase-C (GC-C) agonist. Structurally similar to endogenous guanylin and uroguanylin. Binds GC-C on intestinal epithelial cells, increasing intracellular and extracellular cGMP. Intracellular cGMP activates CFTR chloride channel (fluid secretion, accelerated transit). Extracellular cGMP inhibits nociceptor firing in colonic afferent neurons (visceral analgesia). Minimal systemic absorption — acts locally in GI tract. Phase 3 trials: significant improvement in complete spontaneous bowel movements and abdominal pain.

Effects

## Gastrointestinal System [Tier 1 - FDA-Approved, Extensive Phase III Data] - 14-amino-acid peptide agonist of guanylate cyclase-C (GC-C) receptors on intestinal epithelial cells - Activates GC-C → increases intracellular cGMP → activates CFTR chloride channels → drives chloride and water secretion into intestinal lumen - Net effect: increased intestinal fluid secretion, accelerated colonic transit, and softer stool consistency - FDA-approved for IBS-C and chronic idiopathic constipation (CIC) - Phase III trials showed improvement in complete spontaneous bowel movements (CSBMs) within first week of treatment ## Visceral Pain/Nociception [Tier 1 - Human Data] - Elevated extracellular cGMP (generated by GC-C activation) acts on submucosal pain-sensing nerve fibers - Reduces visceral hypersensitivity — the heightened gut pain sensitivity characteristic of IBS - Patients report reduced abdominal pain independent of bowel frequency improvement - This analgesic effect distinguishes linaclotide from simple osmotic laxatives - Pain reduction typically takes 4-6 weeks to fully manifest (vs. bowel changes in days) ## Immune/Barrier Function [Tier 2 - Preclinical/Mechanistic] - GC-C signaling supports intestinal barrier integrity and epithelial cell turnover - cGMP pathway has anti-inflammatory properties in the gut mucosa - Theoretical protection against colorectal carcinogenesis through GC-C tumor suppressor function (GC-C is often downregulated in colorectal cancer) - Does NOT have systemic absorption — acts locally in the gut lumen ## Systemic Effects [Tier 1 - Human Data] - Minimal systemic absorption (<1% bioavailability) — linaclotide and its active metabolite act entirely within the GI lumen - No meaningful systemic side effects, drug interactions, or endocrine effects - Not metabolized by CYP450 enzymes

Practitioner Guide

## Clinical Positioning Linaclotide (Linzess) is a first-line prescription option for IBS-C and chronic constipation. It is an oral peptide (rare in the peptide world) that works locally in the gut. It is particularly valuable for patients with BOTH constipation and abdominal pain, as it addresses both symptoms through different mechanisms. ## Prescribing - IBS-C: 290mcg oral once daily, on empty stomach, at least 30 minutes before first meal - Chronic idiopathic constipation: 145mcg oral once daily (same timing) - Available as: 72mcg, 145mcg, 290mcg capsules (brand: Linzess) ## Practical Tips - TIMING IS CRITICAL: must be taken on an empty stomach, 30+ minutes before breakfast. Food reduces efficacy. - Onset: bowel frequency improvement within 1 week; abdominal pain improvement may take 4-6 weeks - Diarrhea is the most common side effect (16-20%) — often occurs in first 2 weeks and may resolve. If persistent, reduce dose to 145mcg. - If diarrhea is severe: stop for 1-2 days, restart at lower dose - Can be taken indefinitely — no tachyphylaxis observed in long-term extension studies ## Patient Selection Best candidates: - IBS-C with significant abdominal pain/bloating (the analgesic effect is unique) - Chronic constipation unresponsive to fiber and osmotic laxatives - Patients wanting a non-systemic medication Less ideal: - Patients with IBS-D or mixed pattern (will worsen diarrhea) - Pediatric patients under 6 (contraindicated — risk of severe dehydration) - Patients who cannot take medication on empty stomach reliably ## Linaclotide vs. Plecanatide - Both are GC-C agonists with similar mechanisms - Linaclotide: higher dose range, slightly more potent, more diarrhea side effects - Plecanatide: pH-dependent activation (works best in proximal small intestine pH), may have lower diarrhea rate - Clinical efficacy is similar; choice often comes down to insurance coverage and patient tolerance ## In the Context of Peptide Therapy - Linaclotide is not a "biohacking" peptide — it is a mainstream pharmaceutical - However, it is relevant to peptide therapy patients who have IBS-C or constipation as a comorbidity - Can be used alongside GH peptides, GLP-1 agonists, and other peptides without interaction - GLP-1 agonists commonly CAUSE constipation — linaclotide is an excellent adjunct for this

Dosing Protocols

chronic_constipationbasic tier
Dose
72mcg
Frequency
Once daily on an empty stomach
Timing
Take at least 30 minutes before first meal of the day; swallow capsule whole — do not crush or chew
Route
oral
Cycle
4-52 weeks

FDA-approved (Linzess) 72mcg for chronic idiopathic constipation (CIC). Linaclotide is a 14-amino-acid peptide guanylate cyclase-C (GC-C) agonist that increases intracellular cGMP in intestinal epithelial cells, stimulating chloride and bicarbonate secretion via CFTR, increasing intestinal fluid and accelerating transit. Minimal systemic absorption (<1%) ensures gut-local action. Continuous daily use; no cycling required.

ibs_constipationbasic tier
Dose
290mcg
Frequency
Once daily on an empty stomach
Timing
Take at least 30 minutes before first meal of the day; swallow capsule whole — do not crush or chew
Route
oral
Cycle
4-52 weeks

FDA-approved (Linzess) 290mcg for IBS-C. Higher dose required for IBS-C vs. CIC because visceral pain reduction (via extracellular cGMP modulation of colonic nociceptors) requires greater GC-C agonism. Phase III trials showed significant improvement in abdominal pain and complete spontaneous bowel movements within 1-2 weeks. Diarrhea is the most common adverse effect (20%); if severe, reduce to 72mcg or discontinue. Continuous use; no cycling.

Contraindications & Cautions

  • hard stop — Children under 6 years of age
    BLACK BOX WARNING: Linaclotide (Linzess) is contraindicated in children under 6 years of age. In neonatal mice, linaclotide caused deaths due to dehydration from severe diarrhea. Risk of fatal dehydration in young children.
    Action: Absolutely contraindicated. Do not use in children under 6. This is a black box warning.
  • hard stop — Children 6-17 years of age
    Linaclotide should be avoided in pediatric patients 6-17 years of age per black box warning. Safety and efficacy not established in this age group.
    Action: Avoid use. Not recommended for patients 6-17 years of age per labeling.
  • hard stop — Mechanical GI obstruction
    Linaclotide is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction. Increased intestinal secretion behind an obstruction can cause perforation or severe distension.
    Action: Do not use. Rule out mechanical obstruction before initiating. Labeled contraindication.
  • hard stop — Pregnancy
    Minimal systemic absorption expected, but no adequate human data during pregnancy. Animal studies showed adverse effects at high doses.
    Action: Do not use during pregnancy without physician approval.
  • caution — Severe diarrhea
    Linaclotide commonly causes diarrhea as a side effect. In patients with pre-existing severe diarrhea, it may cause dangerous dehydration and electrolyte imbalances.
    Action: Monitor hydration status. Discontinue if severe diarrhea develops. Ensure adequate fluid intake.

Evidence

Research Summary

## Tier 1 — Phase III/FDA-Approved Human Data - Phase III IBS-C trials (n>1600): linaclotide 290mcg significantly improved abdominal pain, bloating, and CSBM frequency vs. placebo at 12 and 26 weeks - Phase III CIC trials: linaclotide 145mcg improved stool frequency and consistency - Long-term open-label extension: efficacy maintained over 52 weeks with no tachyphylaxis - Diarrhea incidence: 16-20% (most common adverse event), led to discontinuation in ~5% - No serious adverse events above placebo rates; no systemic absorption means excellent safety profile ## Tier 2 — Mechanistic Human Data - Colonic biopsies confirm GC-C receptor expression and cGMP signaling activation - Ussing chamber studies on human intestinal tissue confirm chloride secretion response - Visceral pain threshold testing confirms reduced sensitivity in IBS-C patients after 4+ weeks of treatment - No effect on gastric emptying or upper GI transit — selective colonic action ## Tier 3 — Preclinical - GC-C knockout mice show visceral hypersensitivity and altered bowel habits - cGMP pathway inhibits nociceptor firing in colonic afferent neurons - GC-C agonism suppresses Wnt signaling and may have anti-tumorigenic effects on colonic epithelium - Linaclotide is stable in GI lumen pH but rapidly degraded if absorbed systemically ## Evidence Gaps - No data on use in combination with other peptide therapies (though no mechanistic concern) - Long-term (>5 year) safety data still accumulating from post-marketing surveillance - Optimal dose for GLP-1 agonist-induced constipation not specifically studied - Pediatric dosing not well-established (contraindicated under age 6)

Build a personalized protocol with Linaclotide →